Cargando…
The Qualitative Value of Facilitated Regulatory Pathways in Europe, USA, and Japan: Benefits, Barriers to Utilization, and Suggested Solutions
BACKGROUND: Despite the growing application of facilitated regulatory pathways (FRPs), little attention has focused on assessing the perception of pharmaceutical companies regarding their usefulness beyond increasing timeliness. OBJECTIVES: The aim of this study was to characterize the perceived val...
Autores principales: | Bujar, Magdalena, McAuslane, Neil, Liberti, Lawrence |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7858039/ https://www.ncbi.nlm.nih.gov/pubmed/33537899 http://dx.doi.org/10.1007/s40290-020-00372-7 |
Ejemplares similares
-
FDA Facilitated Regulatory Pathways: Visualizing Their Characteristics, Development, and Authorization Timelines
por: Liberti, Lawrence, et al.
Publicado: (2017) -
To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016
por: Kühler, Thomas Christian, et al.
Publicado: (2019) -
Quality Decision-Making Practices in Pharmaceutical Companies and Regulatory Authorities: Current and Proposed Approaches to Its Documentation
por: Bujar, Magdalena, et al.
Publicado: (2020) -
Evaluating Quality of Decision-Making Processes in Medicines' Development, Regulatory Review, and Health Technology Assessment: A Systematic Review of the Literature
por: Bujar, Magdalena, et al.
Publicado: (2017) -
Use of the Certificate for Pharmaceutical Products (CPP) in 18 Maturing Pharmaceutical Markets: Comparing Agency Guidelines with Company Practice
por: Rodier, Céline, et al.
Publicado: (2020)